Royal Bank Of Canada upgraded shares of Extendicare (TSE:EXE – Free Report) from a hold rating to a moderate buy rating in a research report released on Thursday, Marketbeat reports. Royal Bank Of Canada currently has C$25.00 price target on the stock, up from their previous price target of C$15.00.
EXE has been the subject of several other research reports. Natl Bk Canada upgraded Extendicare to a “strong-buy” rating in a report on Wednesday. CIBC raised their target price on shares of Extendicare from C$18.00 to C$22.00 in a report on Thursday, November 13th. TD Securities upped their price target on shares of Extendicare from C$15.00 to C$19.00 in a research note on Thursday, November 13th. National Bankshares increased their price objective on shares of Extendicare from C$21.50 to C$24.50 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Cibc World Mkts upgraded shares of Extendicare to a “strong-buy” rating in a report on Monday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of C$23.86.
View Our Latest Research Report on EXE
Extendicare Trading Up 1.1%
Extendicare Announces Dividend
The company also recently disclosed a monthly dividend, which was paid on Monday, November 17th. Shareholders of record on Monday, November 17th were paid a $0.042 dividend. The ex-dividend date of this dividend was Friday, October 31st. This represents a c) annualized dividend and a yield of 2.3%. Extendicare’s dividend payout ratio (DPR) is presently 46.60%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Recommended Stories
- Five stocks we like better than Extendicare
- What Are Dividend Challengers?
- Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Gates Foundation Sells MSFT Stock—Should Investors Be Worried?
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 12/1 – 12/5
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
